Systemic Inflammatory Biomarkers in Ovarian Cancer

Completed

• Conditions: Ovarian Cancer
• Interventions: Other: group with complications; Other: group without complications

• Registration Number: NCT06629831
• Lead Sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Brief Summary

In cancer patients, prognostic markers are needed to improve the management and clinical course of both the cancer itself and surgery therefor. Elevated systemic inflammatory markers are associated with morbidity and mortality in most cancer types. In this study, the investigators aimed to determine the prognostic value of inflammatory markers such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) in patients undergoing cytoreductive surgery for ovarian cancer.

Detailed Description

Major gynaecological cancer surgery is a procedure with high complication rates and mortality risk due to both the patient' s old age and comorbidities and the extent of the surgery. Among such surgeries, ovarian cancer-related surgery has the highest mortality rate. Despite advances in early drug therapy and improvements in the cytotoxicity of drugs, ovarian cancer is frequently diagnosed at advanced stages, which further increases morbidity and mortality rates. Although many years have passed, the prognostic role of cytoreductive surgery on survival in ovarian cancers continues to be important. Predicting postoperative outcomes in these surgeries may reduce the length of hospital stay, need for stay in the intensive care unit, complications, and mortality. Therefore, the role of systemic inflammatory biomarkers needs to be comprehensively investigated to understand the carcinogenic mechanisms better.

For this purpose, the investigators planned to evaluate the prognostic effect of systemic inflammatory biomarkers on postoperative complications.

Study Timeline

• Study Start: 2022-12-01
• Primary Completion: 2023-12-01
• Status Verified: 2024-09
• Study Completion: 2024-09-27
• Study First Submitted: 2024-09-27
• Study First Submitted QC: 2024-10-04
• Last Update Submitted: 2024-10-05
• Study First Posted: 2024-10-08
• Last Update Posted: 2024-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 90

Inclusion Criteria

• Patients older than 18 years of age

Exclusion Criteria

• Patients with acute or inflammatory diseases
• Patients with hematological malignancies
• Patients with autoimmune diseases patients who underwent intraoperative hyperchemotherapy (HIPEC)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients undergoing cytoreduction surgery for ovarian cancer	group with complications	Patients undergoing cytoreduction surgery for ovarian cancer
Patients undergoing cytoreduction surgery for ovarian cancer	group without complications	Patients undergoing cytoreduction surgery for ovarian cancer

Primary Outcome Measures

Name	Time	Method
the rate of systemic inflammatory biomarkers	up to 24 hours postoperative	the investigator planned to evaluate the prognostic effect of systemic inflammatory biomarkers on postoperative complications.

Trial Locations

Locations (1)

BasaksehiCam and Sakura City Hospital; 🇹🇷 Istanbul, Turkey